NEWS: Partial verification refers to the situation where a subset of is not verified by the reference (gold) standard and is excluded from the . If partial verification is present, the observed (naive) of accuracy such as sensitivity and specificity are most likely to be biased. Recently, Harel and Zhou showed that partial verification can be considered as a problem and that multiple imputation (MI) methods can be used to correct for this bias. They claim that even in simple situations where the verification is random within strata of the index test , the so-called Begg and Greenes (B&G) correction method underestimates sensitivity and overestimates specificity as compared with the MI method. However, we were able to demonstrate that the B&G method produces similar as MI, and that the claimed difference has been caused by a computational error. Additional is needed to better understand which correction methods should be preferred in more complex scenarios of reference test outcome in diagnostic . Copyright © John Wiley & Sons, Ltd.

Multiple imputation to correct for partial verification bias revisited - Another great article from iHateHospitals.com!

Click to read source…

Hospital Tags: , , , , , , , , , , , , , , , , , , ,

Mesothelioma, Vioxx and Cancer-related posts

NEWS: This article presents a new approach to the problem of deriving an optimal design for a randomized sequential based on right-censored event times. We are motivated by the fact that, if the proportional hazards assumption is not met, then a conventional design’s actual power can differ substantially from its nominal . We combine Bayesian decision theory, Bayesian model and forward simulation (FS) to obtain a sequential procedure that maintains targeted false-positive rate and power, under a wide range of true event time distributions. At each interim , the method adaptively chooses the most likely model and then applies the decision bounds that are optimal under the chosen model. A simulation comparing this design with three conventional designs shows that, over a wide range of distributions, our proposed method performs at least as well as each conventional design, and in maNY (New York) it provides a much smaller . Copyright © John Wiley &; Sons, Ltd.

Bayesian adaptive model for optimizing sequential trials - Another great article from iHateHospitals.com!

Click to read source…

Hospital Tags: , , , , , , , , , , , , , , , , , , ,

Mesothelioma, Vioxx and Cancer-related posts

NEWS: Background:
Animal show that decreased activity of placental 11-beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2), which potently inactivates glucocorticoids (e.g. cortisol) to inert forms (cortisone), allows increased access of maternal glucocorticoids to the fetus and ‘programs’ hypertension. in humans are limited. We examined in humans the association venous umbilical cord blood glucocorticoids, a potential marker for placental 11beta-HSD2 enzyme activity, and blood at age 3 years.
Methods:
Among 286 newborns in Project Viva, a prospective pre-birth based in eastern Massachusetts, we measured cortisol (F) and cortisone (E) in venous cord blood and used the ratio of F/E as a marker for placental 11beta-HSD2 activity. We measured blood (BP) when the offspring reached age 3 years. Using mixed effects regression models to control for BP measurement conditions, maternal and child characteristics, we examined the association the F/E ratio and child BP.
:
At age 3 years, each unit increase in the F/E ratio was associated with a 1.6 mm Hg increase in systolic BP (95% CI 0.0 to 3.1). The F/E ratio was not associated with diastolic blood or birth weight for gestational age z-score.
Conclusions:
A higher F/E ratio in umbilical venous cord blood, likely reflecting reduced placental 11beta-HSD2 activity, was associated with higher systolic blood at age 3 years. Our suggest that increased fetal exposure to active maternal glucocorticoids may program later systolic blood .

Association umbilical cord glucocorticoids and blood at age 3 years - Another great article from iHateHospitals.com!

Click to read source…

Hospital Tags: , , , , , , , , , , , , , , , , , , ,

Mesothelioma, Vioxx and Cancer-related posts

( News) ROCKVILLE, Md. — Human Genome Sciences, Inc. today announced that it has completed the enrollment and initial dosing of in a randomized 2 of HGS-ETR1 (mapatumumab) in with the chemotherapy (serious, serious ) agents paclitaxel and carboplatin as first- in advanced non-small lung (NSCLC). “There is an urgent need for options for non- small lung because current strategies have only a minimal on survival,” said Joachim von Pawel, M.D., a principal investigator in the from the Asklepios Fachkliniken Munchen-Gauting, Germany. “The majority of who are newly diagnosed with non-small lung have locally adv…

Article Source

Human Genome Sciences Completes Enrollment In Randomized 2 Of HGS-ETR1 In Non-small Lung - another great news story, article, or reference from iHateHospitals.com!

Hospital Tags: , , , , , , , , , , , , , , , , , , ,

Mesothelioma, Vioxx and Cancer-related posts

( News) BOTHELL, WA and VANCOUVER — OncoGenex announced today that OGX-011, also known as custirsen , received Fast Track designation from the U.S. Food & Administration () in with docetaxel for progressive metastatic prostate . OGX-011 is currently completing five 2 in prostate, lung and , and is designed to the production of a specific protein, clusterin, associated with resistance. Fast Track designation is granted to products that may provide a significant improvement in the or effectiveness of the for a serious or life-threatening . Based on this designation, the will as appropri…

Article Source

Grants Fast Track Designation For Oncogenex ’ Lead Product Candidate OGX-011 - another great news story, article, or reference from iHateHospitals.com!

Hospital Tags: , , , , , , , , , , , , , , , , , , ,

Mesothelioma, Vioxx and Cancer-related posts




Welcome to iHateHospitals.com - your one-stop source for medical and health information. Get all the latest health news and medical articles - updated 24/7/365!

Whether you're researching an illness, searching for a good doctor, looking up signs and symptoms, finding a well-respected hospital or care center - you'll find it all here!